UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event
reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File No.) |
(IRS Employer Identification No.) |
(Address of principal executive offices) |
(Zip Code) |
(
(Registrant’s telephone number, including area code)
NOT APPLICABLE
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 | Other Events. |
On February 1, 2023, vTv Therapeutics Inc. (the “Company”) announced that the board of directors of the Company has appointed Elizabeth Keiley as Executive Vice President and General Counsel of the Company, effectively immediately. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit Number |
Description | |
99.1 | Press Release | |
104 | Cover Page Interactive Data File (embedded within Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
VTV THERAPEUTICS INC. | |||
By: | /s/ Paul J. Sekhri | ||
Name: | Paul J. Sekhri | ||
Title: | Chief Executive Officer |
Dated: February 1, 2023
EXHIBIT 99.1
Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics
HIGH POINT, N.C., February 1, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of Elizabeth (Betzy) Keiley as Executive Vice President and General Counsel, effective immediately.
“We welcome Betzy to vTv. Her years of legal expertise and deep experience in life sciences will be valuable to the vTv team,” said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics. “Her decades of experience in both private practice and corporate settings make her an ideal fit for this position. I am confident that we will benefit from her contributions and look forward to working closely with her as we move ahead toward our long-term capital funding goals and launching our phase 3 clinical trials.”
Ms. Keiley is an accomplished life science industry attorney who has served in multiple senior-level legal positions at publicly traded biotechnology, diagnostic and medical device companies. She joins vTv from Entasis Therapeutics Holdings Inc., where she served as General Counsel. Prior to Entasis, she was Senior Vice President, General Counsel at Oxford Immunotec, where she simultaneously served for seven years as Chief Compliance Officer, and was Assistant General Counsel, Americas, of Zimmer, Inc., a subsidiary of Zimmer Holdings, Inc. Before beginning her corporate career in 2008, Ms. Keiley was a partner at Wildman, Harrold, Allen & Dixon LLP in Chicago, Illinois, where she focused on a wide range of corporate and commercial matters for clients in a variety of industries, including medical devices. Ms. Keiley earned her bachelor’s degree in Psychology and Philosophy from Boston College and a J.D. from Loyola University School of Law.
“With the upcoming initiation of our pivotal studies of TTP399, the company is approaching a key inflection point with the potential to become a commercial organization in the coming years,” added Ms. Keiley. “I am eager to put my skills and expertise to work as we continue to advance the development of TTP399 toward our ultimate goal of changing the treatment paradigm for patients with T1D.”
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes and cystic fibrosis related diabetes. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease, renal disease, primary mitochondrial myopathy, and pancreatic cancer. For more information, please visit www.vtvtherapeutics.com.
Forward-Looking Statements
The statements made in this release may include forward-looking statements regarding (i) diabetes market and other markets, (ii) the development and clinical trial process, regulatory approval process and attributes of investigational and marketed products to treat these diseases and other conditions, and (iii) the future operations, fund-raising activities, expenditures, opportunities and financial performance of vTv Therapeutics Inc.
These forward-looking statements are only estimates based upon the information available to vTv Therapeutics Inc. (or the party preparing such forward-looking statements) as of the date of this release. The forward-looking statements included herein involve known and unknown risks and uncertainties and other important factors such that actual future operations, opportunities, product development processes and outcomes, clinical trial processes and outcomes, regulatory approval processes and outcomes, economic performance of products, fund-raising activities and financial performance may differ materially from those set forth in or implied in these forward-looking statements. These risks, uncertainties, and other factors, which may not be within our control, are discussed in more detail in our quarterly and annual reports filed with the Securities and Exchange Commission, including, without limitation, under the captions, “Risk Factors,” “Cautionary Note Regarding Forward-Looking Statements” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Therefore, you should read this release in conjunction with such meaningful cautionary statements.
Undue reliance should not be placed on forward-looking statements, which speak only as of the date hereof. Except as required by law, we expressly disclaim any responsibility to publicly update or revise our forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements contained herein are qualified in their entirety by the foregoing cautionary statements.
This release is being provided to you for information purposes only. This release does not constitute an offer or sale of (or the solicitation of an offer to buy) any securities of vTv Therapeutics Inc. or any of its subsidiaries.
This release should not be relied upon for making any investment decision with respect to any securities of vTv Therapeutics Inc. or any of its subsidiaries. Any investment decision made with respect to any such securities should be based solely on an offering document relating to such securities (if any), including the information incorporated by reference therein.
Contacts:
Investors:
Lee Roth
Burns McClellan
lroth@burnsmc.com
Media:
Selina Husain / Robert Flamm, Ph.D.
Burns McClellan, Inc.
shusain@burnsmc.com / rflamm@burnsmc.com